Skip to content

ED95 bupivacaine and supraclavicular block

What is the ED95 dose for bupivacaine for supraclavicular brachial plexus block using ultrasound?

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN63230740
Enrollment
40
Registered
2010-04-29
Start date
2009-10-05
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Generic Health Relevance and Cross Cutting Themes

Interventions

Primary outcome is the success or failure of the supraclavicular block. This will be assessed by testing the patient's ability to detect cold sensation by application of a cold alcohol swab to the ski

Sponsors

University of Leeds (UK)
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. American Society of Anaesthesiologists (ASA) 1 - 3 patients 2. Aged greater than 18 years, either sex 3. Routine hand, forearm or upper limb surgery

Exclusion criteria

Exclusion criteria: 1. ASA greater than 3 2. Aged less than 18 years 3. Allergy to bupivacaine 4. Unable to give written informed consent 5. Body Mass Index greater than 35 kg/m^2 6. Pregnant women

Design outcomes

Primary

MeasureTime frame
Ability to detect cold sensation by application of cold alcohol swab to the skin at the sensory dermatomes of the median, ulnar, radial and musculocutaneous nerves in the upper limb, measured 45 minutes after performing the supraclavicular block.

Secondary

MeasureTime frame
No secondary outcome measures

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026